Loading...

Course Description

This presentation will be a practical review of canine myxomatous mitral valve disease (MMVD), diagnostics and the renin-angiotensin-aldosterone system (RAAS). While the RAAS system is a life-saver in acute, hypovolemic situations such as blood loss, this system causes deleterious effects when left unchecked long term. The canine MMVD patient has decreased cardiac output which triggers RAAS activation. We will review the consequences of chronic long term RAAS activation. We will discuss the importance of its management along with a practical review of the diagnostic approach to canine mitral valve disease. The 2019 ACVIM consensus guidelines for myxomatous mitral valve disease (MMVD) in dogs will be reviewed highlighting the recommended classification system and corresponding treatments. The 2019 ACVIM treatment guidelines recommend a quad-therapy approach. We will discuss why and what that means for your MMVD patients.

Benefits to the Learner

  • Utilize the most recent diagnostic techniques to assess the degree of cardiac enlargement due to MMVD utilizing the 2019 ACVIM MMVD consensus guidelines
  • Understand the consequences of MMVD and recognize the signalment in the canine population
  • Understand the need for spironolactone use in RAAS suppression

Accrediting Associations

Loading...
Thank you for your interest in this course. Unfortunately, the course you have selected is currently not open for enrollment. Please complete a Course Inquiry so that we may promptly notify you when enrollment opens.
Required fields are indicated by .